Project Summary

Finerenone API is a novel, selective non-steroidal mineralocorticoid receptor antagonist (MRA). It significantly reduces the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes, with full cGMP manufacturing and USDMF documentation.